-
Exchange | NASDAQ |
---|---|
CurrencyCode | USD |
ISIN | US23254L2079 |
Sector | Healthcare |
Industry | Biotechnology |
Market Cap | 10M |
---|---|
PE Ratio | None |
Target Price | None |
Dividend Yield | 0.0% |
Beta | 0.16 |
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CYCCP using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025